New Clinical Report about Tomosynthesis Utilization for COVID-19 Pneumonia Diagnosis
New Clinical Report about Tomosynthesis Utilization for COVID-19 Pneumonia Diagnosis Read more
Category: Clinical Research/Diagn.
Zymo Research Obtains CE IVD Mark for Its Quick SARS-CoV-2 Multiplex Kit
LOW COST, HIGH-SENSITIVITY DIAGNOSTIC TEST FOR COVID-19 DETECTION Zymo Research was recently granted the CE IVD certification for its Quick SARS-CoV-2 Multiplex Kit. IRVINE, Calif., (Nov. 10, 2020) — Zymo Research announced today that it obtained a CE IVD mark for the Quick SARS-CoV-2 Multiplex Kit in compliance with the Directive 98/79/EC of the European Parliament and of... Read more
Bringing Ultra-High Field MR Imaging from Research to Clinical: SIGNA 7.0T FDA Cleared
Waukesha, WI – November 10, 2020 – GE Healthcare today announced U.S. FDA 510(k) clearance of SIGNA 7.0T magnetic resonance imaging (MRI) scanner, the world’s most powerful FDA-cleared MRI device available. With a magnet approximately five times more powerful than most clinical systems, SIGNA 7.0T https://www.ge.com/news/press-releases/bringing-ultra-high-field-mr-imaging-from-research-to-clinical-signa-70t-fda-cleared Read more
Fluidigm and Healthvana Partner to Offer COVID-19 Test Results Delivery through Innovative Digital Platform
Patients Receive Results, Education and Next Steps on Their Mobile Phones to Prevent Further Spread of the Disease SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) — Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it has partnered with Healthvana Inc., the nation’s leading patient platform... Read more
Tampa General Hospital and GE Healthcare's CareComm Saves $40 Million, Cuts 20,000 Excess Days and Reduces Length of Stay
Tampa, FL – October 29, 2020 – Tampa General Hospital (TGH), in partnership with GE Healthcare, reports a $40M reduction of system-wide inefficiencies since launching their CareComm command center with GE’s Command Center Software last August. Utilizing 20 artificial intelligence applications (aka Tiles), CareComm helps to optimize minute-to-minute patient care operations with real-time actionable information used in CareComm... Read more
Tampa General Hospital and GE Healthcare's CareComm Saves $40 Million, Cuts 20,000 Excess Days and Reduces Length of Stay
Tampa, FL – October 29, 2020 – Tampa General Hospital (TGH), in partnership with GE Healthcare, reports a $40M reduction of system-wide inefficiencies since launching their CareComm command center with GE’s Command Center Software last August. Utilizing 20 artificial intelligence applications (aka https://www.ge.com/news/press-releases/tampa-general-hospital-and-ge-healthcares-carecomm-saves-40-million-cuts-20000 Read more
Thermo Fisher Scientific Expands Direct-to-Patient Clinical Trials Service Offerings
Thermo Fisher Scientific Expands Direct-to-Patient Clinical Trials Service Offerings End-to-end solution accelerates clinical trials with speed, convenience and quality WALTHAM, Mass., Oct. 27, 2020 /PRNewswire/ — A newly expanded Direct-to-Patient service offering supports decentralized clinical trials to minimize clinical trial length and costs while maximizing patient enrollment and participation rates. The comprehensive offering now includes... Read more
PerkinElmer Launches Industry First No-Wash Immunoassay For Phospho Ubiquitin Ser65 to Help Drive Neuroscience Disease and Therapeutics Research Forward
New kit provides highly sensitive and efficient approach for studying mitophagyimpairment in conditions such as Parkinson’s and Alzheimer’s WALTHAM, Mass. – October 26, 2020 – PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today launched the life science industry’s first no wash Ubiquitin phosphorylation at Serine 65 immunoassay for studying defective... Read more
Invitae and Pacific Biosciences Collaborate to Develop Whole Genome Sequencing-Based Assays for Pediatric Epilepsy Diagnostics
SAN FRANCISCO and MENLO PARK, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) — Invitae Corporation (NYSE: NVTA), a leading genetics company, and Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced a research collaboration focused on the investigation of clinically relevant molecular targets for use in... Read more